Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549049 · ClinicalTrials.gov registry record · NA
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
A NA study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- NA
- Development phase
- 182
- Enrollment target
NCT06549049: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT06549049 is a NA study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06549049, a NA study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
Study Summary
Sleep disturbance is a major problem in Veterans with posttraumatic stress disorder (PTSD). This study will test a version of a sleep treatment that's been shown to be effective in the general population, with some changes to tailor it to the needs of Veterans with PTSD and sleep disturbance.
Primary Outcome
The WHODAS is a validated, comprehensive measure of health-related disability.
Interventions
- BEHAVIORAL TranS-C for PTSD
- BEHAVIORAL Sleep Psychoeducation Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
What is known before NCT06549049 opens enrollment
NCT06549049 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which TranS-C for PTSD is the first listed.
NCT06549049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06549049 about?
NCT06549049 is a clinical study titled "A Transdiagnostic Sleep Health Intervention for Veterans With PTSD". Sleep disturbance is a major problem in Veterans with posttraumatic stress disorder (PTSD). This study will test a version of a sleep treatment that's been shown to be effective in the general population, with some changes to tailor it to the needs of Veterans with PTSD and sleep disturbance.
What is the current status of trial NCT06549049?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 182 participants. The study started on 2026-09-01. Estimated completion is 2029-01-31.
What interventions are being tested in trial NCT06549049?
The interventions under investigation include: TranS-C for PTSD (BEHAVIORAL), Sleep Psychoeducation Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT06549049?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06549049's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI